Clinical trial
Homocysteine Lowering and Atherosclerosis Reduction Trial (HART)
NCT00217178 · Hamilton Health Sciences Corporation, Other · Unknown status
Key facts
| NCT number | NCT00217178 |
|---|---|
| Title | Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) |
| Official title | Homocysteine Lowering and Atherosclerosis Reduction Trial (HART) |
| Lead sponsor | Hamilton Health Sciences Corporation, Other |
| Collaborators | Canadian Institutes of Health Research (CIHR) Population Health Research Institute |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Atherosclerosis, Cardiovascular Disease |
| Intervention type | Drug |
| Interventions | Vitamins: Folic acid, B6, B12 |
| Enrollment | 900 |
| Start date | Jan 1, 2000 |
| Completion | Oct 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Sep 22, 2005 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: